基因编辑权威指南。
菜单
首页 学习 新闻 向 Atlas 提问
探索 技术 疾病 治疗方法 临床试验 企业 科学家 基因 研究 机构
医学之外 农业 伦理 投资 世界地图
学习与工具 从这里开始 术语表 A–Z 对比技术 时间线 列表与排名 AI 智能体 ★ 已保存 API
关于 关于我们 方法论 数据来源 编辑方针 联系我们 免责声明

🧭 引导视图
遗传学新手?浏览时我们会用简单易懂的语言为您解释每个术语,就在同一页面内,帮助随时可用。

⚡ 专家观点
你已经了解生物学基础,只需内容本身——简洁明了,无额外解释。这是默认视图。

界面语言
浅色模式

对比

Ex Vivo vs In Vivo Gene Editing

Editing cells outside the body and giving them back, against editing them where they already are.

一句话说清两者的区别

Ex vivo means the cells come out, get edited in a facility, get checked, and go back — which is safer in one important way, because you can inspect the product first, and much harder on the patient, because it requires chemotherapy and weeks in hospital. In vivo means an infusion. Easier for the patient, and nothing can be checked before it happens.

方面Ex vivoIn vivo
Where editing happens In a manufacturing facility Inside the patient's body
Can the product be checked first? Yes — tested and released before use No
Patient burden High — apheresis, conditioning chemotherapy, weeks in hospital Low — an infusion
Which cells can be reached Blood and immune cells, mostly Whatever the delivery vehicle reaches
If something goes wrong The product can be discarded before administration It cannot be withdrawn
Cost and complexity Very high — a bespoke product per patient Lower — a manufactured medicine
Approved example Casgevy None yet

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.